Ropes & Gray Advises Cubist Pharmaceuticals in $9.5 Billion Acquisition by Merck

In The News
December 8, 2014

Ropes & Gray advised Cubist Pharmaceuticals, Inc. in its acquisition by Merck, which agreed to acquire Cubist for $102 per share in cash.  The total transaction value, including debt, is approximately $9.5 billion. Cubist, a leading global biopharmaceutical company based in Lexington, Mass., focuses on the research, development and supply of antibiotics to treat infections caused by a broad range of drug-resistant bacteria. The deal was announced Dec. 8.

The Ropes & Gray team included partners Christopher Comeau and Paul Kinsella and associate Zachary Blume.